Clinical Trial Update: A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety and preliminary efficacy of ATA3219 in systemic lupus erythematosus and lupus nephritis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis
• Systemic Lupus Erythematosus

Drugs mentioned

• ATA3219

Snippet

Sponsor: Atara Biotherapeutics | Conditions: Lupus Nephritis, Systemic Lupus Erythematosus | Phase 1 | Status: WITHDRAWN